Efficacy of the Arbekacin and Teicoplanin Combination on Glycopeptide Intermediate Staphylococcus aureus in a Rabbit Model of Endocarditis.
- Author:
Cheong Ho CHO
1
;
Jun Yong CHOI
;
Sang Hoon HAN
;
Han Sung LEE
;
Suk Hoon CHOI
;
Bum Sik CHIN
;
Hee Kyoung CHOI
;
Su Jin JEOUNG
;
Myung Soo KIM
;
Chang Oh KIM
;
Chang Ki KIM
;
Dongeun YONG
;
Young Goo SONG
;
Kyungwon LEE
;
June Myung KIM
Author Information
- Publication Type:Original Article
- Keywords: Endocarditis; Staphylococcus aureus; Teicoplanin; Arbekacin
- MeSH: Aortic Valve; Body Weight; Dibekacin; Endocarditis; Sprains and Strains; Staphylococcus; Staphylococcus aureus; Teicoplanin
- From: Infection and Chemotherapy 2008;40(2):102-106
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: There have been no reports to evaluate the usefulness of combination therapy with glycopeptide and arbekacin in endocarditis by in vivo model. MATERIALS AND METHODS: We investigated the efficacy of the arbekacin and teicoplanin combination on glycopeptide intermediate Staphylococcus aureus (GISA) in rabbit model of endocardits. GISA Mu50 strain was used for the experiment. The rabbit model of aortic valve endocarditis as described previously was used. Treatment was started 20h later inoculation with teicoplanin alone (at 20 mg/kg of body weight intramuscularly every 12 hours for 4 days after loading dose of 40 mg/kg of body weight intramuscularly), arbekacin alone (5 mg/kg of body weight intramuscularly every 12h for 4 days), or teicoplanin plus arbekacin. The results of therapy for experimental endocarditis due to Mu50 showed that teicoplanin and arbekacin combination was more effective than the administration of both drugs alone in reducing the log10CFU/g of aortic vegetation (P<0.05). CONCLUSION: The combination of teicoplanin and arbekacin was more effective against GISA (Mu50) than both drugs alone in vivo endocarditis model.
